Table 2 Summary of outcomes and findings of cases with primary pure angiosarcomas of the ovary reported
From: Primary ovarian angiosarcoma: a rare and recognizable ovarian tumor
Literature | Case ID | Age, yr | Size, cm | Stage | Position | Follow up | Postoperative adjuvant therapy |
|---|---|---|---|---|---|---|---|
Patel et al., 1991 [13] | 1 | 42 | Not available | IV | Right | DOD, 18 days | None |
Cunningham et al., 1994 [14] | 2 | 19 | 12 × 10 | IV | Left | DOD, 7 mo | Doxo/ifos, 4 cycles; cisplat-num/etoposide, 1 cycle |
Nara et al., 1996 [15] | 3 | 33 | 4 | IV | Right | DOD, 2 mo | None |
Nielsen et al., 1997 [16] | 4 | I | NED | None | |||
5 | I | 5.5 yr–9 yr | |||||
6 | I | ||||||
7 | 20–32 | 6–13 | I | Not available | |||
8 | III | DOD, 2 mo | |||||
Furihata et al, 1998 [17] | 9 | 46 | 21 × 16 × 13 | Not available | Right | DOD, 9 mo | Cisplatin, 1 cycle; radiation |
Lifschnitz-Mercer et al, 1998 [9] | 10 | 25 | 13 × 11 × 5 | III | Left | Recurrent disease, 18 mo+ | Doxo/ifos, 3 cycles |
Nucci et al, 1998 [18] | 11 | 35 | IV | Not available | DOD “quickly” | None | |
I | Left | ||||||
12 | 25 | 3.5–14 | III | Not available | NED, 3 mo | ||
13 | 42 | DOD, 2 yr | |||||
I | Right | ||||||
14 | 27 | NED,14 mo | |||||
Platt et al., 1999 [19] | 15 | 40 | 11 × 8 | IV | Left | NED, 2 mo | MAID, 4 cycles |
Twu et al., 1999 [20] | 16 | 40 | Not available | IV | Bilateral | DOD, 7 mo | Doxo/ifos, 8 cycles |
Davidson et al., 2005 [21] | 17 | 19 | 18 × 15 × 15 | III | Left | DOD, 1 yr | Doxo/ifos, 6 cycles |
QuesenbErr et al., 2005 [22] | 18 | 31 | 19 × 16 ×8.5 | IC | Left | NED,1 yr | MAID, 3 cycles |
Jha et al., 2005 [23] | 19 | 28 | 20 × 25 | I | Right | NED,10 mo | Doxo/ifos, 6 cycles |
Vavilis et al., 2007 [24] | 20 | 29 | 8 × 6 | Not available | Right | Not available | None |
Bradford et al., 2010 [25] | 21 | 67 | 12 × 6 × 8 | IIIC | Right | DOD,1 mo | Paclitaxel, 1 cycle |
Serrano et al., 2010 [26] | 22 | 23 | 14 | IIIC | Left | NED,12 mo | Epirubicin/ifos, 6 cycles |
Iljazovic et al., 2011 [27] | 23 | 11 | Left: 17 × 14 × 6 Right: 14 × 7 × 5 | IIA | Bilateral | NED, 10 mo | Chemotherapy, 6 cycles |
Bosmuller et al., 2011 [11] | 24 | 81 | 30 × 18 ×12 | I | Right | NED, 5 mo | Doxo, 4 cycles |
Guseh et al., 2012 [28] | 25 | 40 | 15 × 11 × 2 | IIIC | Right | Recurrent disease, 18mo+ | Doxo/ifos, 3 cycles |
Yaqoob et al., 2014 [29] | 26 | 41 | 7 × 6 × 2 | IA | Left | Not available | None |
Wu et al., 2014 [30] | 27 | 45 | Left: 7.1 × 4.7 Right: 2.1 × 1.4 | IIIA | Bilateral | DOD, 30 mo | MAID, 6 cycles |
Gaiolla et al., 2014 [31] | 28 | 71 | 4.4 | Not available | Right | DOD, 27mo | Gemcitabine/zoledronic acid, 2 cycles |
Darre et al., 2017 [32] | 29 | 12 | 17 × 14 × 9 | II | Right | NED “not afford it” | None |
Priyakumari et al., 2018 [33] | 30 | 11 | 15 × 10 × 8 | Not available | Right | NED “unwilling for treatment” | None |
Pariury et al., 2019 [34] | 31 | 11 | Not available | Not available | Right | NED, 43 mo | Demcitabine/doxo, 12 cycles |
Current case | 32 | 47 | 7 × 4 × 4 | I | Left | NED, 8 mo+ | Olaparib, anti-PD-1 |